Berobenatide acetate (PF-08653944 acetate; MET-097 acetate) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide acetate induces weight loss in diet-induced obese mice. Berobenatide acetate can be used in obesity-related research [1] [2].
In Vivo, Berobenatide (0.24-0.8 nmol/kg; subcutaneous injection; once daily; administered for 22 days, with double doses on day 7 and day 14) acetate induces a significantly greater body weight loss in DIO mice than Semaglutide and Tirzepatide [1].
References:
[1]. Hinds C, et al. MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist. Diabetes, 2025, 74(Supplement_1): 794-P.
[2]. Lee S, et al. A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals (Basel, Switzerland). 2026 Jul 07;19(7):1047.
In Vivo, Berobenatide (0.24-0.8 nmol/kg; subcutaneous injection; once daily; administered for 22 days, with double doses on day 7 and day 14) acetate induces a significantly greater body weight loss in DIO mice than Semaglutide and Tirzepatide [1].
References:
[1]. Hinds C, et al. MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist. Diabetes, 2025, 74(Supplement_1): 794-P.
[2]. Lee S, et al. A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals (Basel, Switzerland). 2026 Jul 07;19(7):1047.